Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Phase I of the study is designed to determine the recommended phase II dose (RP2D) for
tazemetostat in patients treated with 8 cycles of R-CHOP 21.
Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in
DLBCL and FL patients :
DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat
with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of
tazemetostat and 24 months of Rituximab